iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
NYS DURB HCV Mtg Feb 26
 
 
  Download the PDF here
 
Medicaid Drug Utilization Review Board
Meeting Agenda for February 26, 2015

The Drug Utilization Review (DUR) Board will meet on
February 26, 2015 from 9:00 a.m. to 4:00 p.m.
Meeting Room 6, Concourse,
Empire State Plaza, Albany, New York
 
http://www.health.ny.gov/health_care/medicaid/program/dur/meetings/2015/index.htm
 
Hepatitis C Virus - Recently Approved Therapies
(ombitasvir/paritaprevir/ritonavir with dasabuvir - Viekira)
 
The Hepatitis C Virus agenda item will also include a Preferred Drug Program (PDP) review of new clinical and financial information for the Hepatitis C - Direct Acting Antiviral therapeutic class (PDP class listed below). The Board will review new clinical and financial information and recommend preferred or non-preferred status for products within the therapeutic class.
 
Hepatitis C - Direct Acting Antivirals
Copegus (ribavirin), Harvoni (ledipasvir/sofosbuvir), Moderiba (ribavirin), Olysio (simeprevir), Rebetol (ribavirin), Ribapak (ribavirin), Ribasphere (ribavirin), ribavirin, Sovaldi (sofosbuvir), Victrelis (boceprevir), Viekira (ombitasvir/paritaprevir/ritonavir with dasabuvir)
 
The current preferred or non-preferred status of products in the Hepatitis C - Direct Acting Antiviral therapeutic class may be viewed at:
https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf
 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org